Bershteyn Lab

Research focus

NIH R01 · 2025

Drug concentration measurement for HIV prevention targets: toward a population-based HIV impact assessment (PHIA) for PrEP

Sub-Saharan Africa (SSA) is home to two-thirds of all people living with HIV (PLHIV). Widely-adopted targets such as “95-95-95” (diagnosing ≥95% of PLHIV, treating ≥95% of those diagnosed, and achieving viral load suppression in ≥95% of those on treatment) have fueled tremendous progress in access and effective use of HIV treatment, with surveillance from Population HIV Impact Assessments (PHIAs) used to monitor progress. Although these efforts have reduced HIV incidence and mortality, HIV/AIDS remains the leading cause of death among SSA adults, and HIV incidence remains high, with many regions not on track to achieve the Sustainable Development Goal (SDG) of HIV incidence <0.1% per…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.